Contents

Search


glipizide (Glucotrol, Glucotrol XL)

Tradename: Glucotrol, Glucotrol XL. 2nd generation sulfonylurea. Indications: management of diabetes mellitus type 2* * may be preferred agent in patients with renal insufficiency Dosage: 1) start: 2.5-5 mg PO QD 2) increase: 2.5-5 mg QD weekly 3) max** 40 mg/day 4) divide dose BID if >15 mg/day 5) geriatrics: begin 2.5 mg QD, QD dosing Tabs: 5 & 10 mg. **Doses > 10 mg/day may not provide additional benefit. Pharmacokinetics: 1) onset of action 1.5 hours 2) food delays absorption [3] 3) protein binding: 92-99% 4) metabolized in the liver (91-97%) 5) elimination 1/2life of 2-4 hours 6) duration of action: up to 24 hours 7) 60-80% of metabolites eliminated in the urine, 11% in the feces Adverse effects: 1) common (> 10%) - headache - constipation - diarrhea - heartburn - anorexia - epigastric fullness - dizziness 2) less common (1-10%) - skin rash, hives, photosensitivity 3) uncommon (< 1%) - aplastic anemia, hemolytic anemia, bone marrow depression, cholestatic jaundice, thrombocytopenia, agranulocytosis, hypoglycemia 4) produces less hypoglycemia following a prolonged fast than does glyburide [5] Drug interactions: 1) alcohol 2) beta adrenergic receptor antagonists 3) non-steroidal anti-inflammatory agents 4) hypoglycemia may occur in combination with clarithromycin [7] Laboratory: - glipizide in specimen - glipizide in serum/plasma - glipizide in urine

Interactions

drug interactions drug adverse effects (more general classes) monitor with sulfonylureas

Related

glipizide/metformin (Metaglip)

General

sulfonylurea

Properties

MISC-INFO: elimination route LIVER KIDNEY protein-binding 92-99% 1/2life 7 HOURS pregnancy-category C safety in lactation ?

Database Correlations

PUBCHEM correlations

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
  2. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  3. Harrison's Principles of Internal Medicine, 14th ed. Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 470
  4. Geriatric Dosage Handbook, 6th edition, Selma et al eds, Lexi-Comp, Cleveland, 2001
  5. Shorr RI, JAMA 279(18):1441-a, 1998 http://jama.ama-assn.org/cgi/content/full/279/18/1441-a
  6. Department of Veterans Affairs, VA National Formulary
  7. Paauw DS Dangerous and Deadly Drug Combinations Medscape. June 30, 2016 http://www.medscape.com/features/slideshow/dangerous-drug-combinations

Component-of

glipizide/metformin (Metaglip)